Suzhou Fushilai Pharmaceutical Co. Ltd. (SHE:301258) — Market Cap & Net Worth
Market Cap & Net Worth: Suzhou Fushilai Pharmaceutical Co. Ltd. (301258)
Suzhou Fushilai Pharmaceutical Co. Ltd. (SHE:301258) has a market capitalization of $331.60 Million (CN¥2.27 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #14452 globally and #4319 in its home market, demonstrating a -2.60% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Suzhou Fushilai Pharmaceutical Co. Ltd.'s stock price CN¥24.72 by its total outstanding shares 91670000 (91.67 Million). Also see 301258 asset base for a full breakdown of the balance sheet.
Suzhou Fushilai Pharmaceutical Co. Ltd. Market Cap History: 2022 to 2026
Suzhou Fushilai Pharmaceutical Co. Ltd.'s market capitalization history from 2022 to 2026. Data shows change from $507.25 Million to $331.60 Million (-19.00% CAGR). Also see Suzhou Fushilai Pharmaceutical Co. Ltd. cash conversion from operations for how efficiently the company converts equity into cash flow.
Suzhou Fushilai Pharmaceutical Co. Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Suzhou Fushilai Pharmaceutical Co. Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 301258 stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.74x
Suzhou Fushilai Pharmaceutical Co. Ltd.'s market cap is 0.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
19.31x
Suzhou Fushilai Pharmaceutical Co. Ltd.'s market cap is 19.31 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $507.25 Million | $568.21 Million | $177.31 Million | 0.89x | 2.86x |
| 2023 | $423.38 Million | $489.29 Million | $112.18 Million | 0.87x | 3.77x |
| 2024 | $316.84 Million | $429.47 Million | $16.41 Million | 0.74x | 19.31x |
Competitor Companies of 301258 by Market Capitalization
Companies near Suzhou Fushilai Pharmaceutical Co. Ltd. in the global market cap rankings as of September 19, 2026. Review how tangible is Suzhou Fushilai Pharmaceutical Co. Ltd.'s equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Suzhou Fushilai Pharmaceutical Co. Ltd. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Suzhou Fushilai Pharmaceutical Co. Ltd. Historical Marketcap From 2022 to 2026
Between 2022 and today, Suzhou Fushilai Pharmaceutical Co. Ltd.'s market cap moved from $507.25 Million to $ 331.60 Million, with a yearly change of -19.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥331.60 Million | -23.94% |
| 2025 | CN¥435.96 Million | +37.60% |
| 2024 | CN¥316.84 Million | -25.16% |
| 2023 | CN¥423.38 Million | -16.53% |
| 2022 | CN¥507.25 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Suzhou Fushilai Pharmaceutical Co. Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $331.60 Million USD |
| MoneyControl | $331.60 Million USD |
| MarketWatch | $331.60 Million USD |
| marketcap.company | $331.60 Million USD |
| Reuters | $331.60 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Suzhou Fushilai Pharmaceutical Co. Ltd.
Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and … Read more